FindTrial
Sign In

placebo for ustekinumab

DRUG4 trials

Sponsors

Janssen Research & Development, LLC, AbbVie, Janssen Scientific Affairs, LLC

Conditions

Crohn DiseasePsoriasis

Phase 3

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
CompletedNCT02203032
Janssen Research & Development, LLCPsoriasis
Start: 2014-10-07End: 2016-05-24Updated: 2017-09-12
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
CompletedNCT02684370
AbbViePsoriasis
Start: 2016-02-29End: 2017-09-30Updated: 2021-07-30
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
CompletedNCT02684357
AbbViePsoriasis
Start: 2016-03-31End: 2017-09-30Updated: 2021-08-23
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
CompletedNCT03464136
Janssen Scientific Affairs, LLCCrohn Disease
Start: 2018-03-29End: 2021-05-21Updated: 2025-04-29

Related Papers

Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.
2025-12-01
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.
2024-10-022 citations
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.
2024-09-124 citations
Deep Learning-Based Psoriasis Assessment: Harnessing Clinical Trial Imaging for Accurate Psoriasis Area Severity Index Prediction
Digital Biomarkers2024-03-047 citations
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (<scp>LIMMitless</scp> trial)
Journal of the European Academy of Dermatology and Venereology2024-01-0513 citations
Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study
SKIN The Journal of Cutaneous Medicine2023-11-13
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
2023-10-3131 citations
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dermatology and Therapy2022-08-026 citations
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
Journal of Dermatological Treatment2022-07-156 citations
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
2022-06-01203 citations
Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
Dermatology and Therapy2021-12-186 citations
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model.
2021-05-215 citations
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis
JAMA Dermatology2020-10-1452 citations
Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
2020-05-0116 citations
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
Journal of the European Academy of Dermatology and Venereology2020-04-2257 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
2019-10-0123 citations
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
2018-08-07460 citations